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Summary
 
Fas is a cell surface receptor that transduces cell death signals when cross-linked by agonist anti-
bodies or by fas ligand. In this study, we examined the potential of fas to contribute to oligo-
dendrocyte (OL) injury and demyelination as they occur in the human demyelinating disease
multiple sclerosis (MS). Immunohistochemical study of central nervous system (CNS) tissue
from MS subjects demonstrated elevated fas expression on OLs in chronic active and chronic
silent MS lesions compared with OLs in control tissue from subjects with or without other
neurologic diseases. In such lesions, microglia and infiltrating lymphocytes displayed intense
immunoreactivity to fas ligand. In dissociated glial cell cultures prepared from human adult
CNS tissue, fas expression was restricted to OLs. Fas ligation with the anti-fas monoclonal an-
tibody M3 or with the fas–ligand induced rapid OL cell membrane lysis, assessed by LDH re-
lease and trypan blue uptake and subsequent cell death. In contrast to the activity of fas in other
cellular systems, dying OLs did not exhibit evidence of apoptosis, assessed morphologically and
by terminal transferase–mediated d-uridine triphosphate-biotin nick-end-labeling staining for
DNA fragmentation. Other stimuli such as C2-ceramide were capable of inducing rapid apop-
tosis in OLs. Antibodies directed at other surface molecules expressed on OLs or the M33 non-
activating anti-fas monoclonal antibody did not induce cytolysis of OLs. Our results suggest
that fas-mediated signaling might contribute in a novel cytolytic manner to immune-mediated
OL injury in MS.
 
M
 
ultiple sclerosis (MS)
 
1
 
 is a progressive disease of the
central nervous system (CNS) and characterized by
multifocal areas of inflammation and demyelination (1–4).
The disease is considered to be immune-mediated and di-
rected at myelin and its cell of origin, the oligodendrocyte
(OL; 4). The precise basis for this selective injury remains
to be established. Depletion of OLs is a recognized feature
of MS lesions, becoming more apparent as the disease
evolves (5). Examples of OLs undergoing lytic (3, 4) or
apoptotic (6, 7) cell death in situ in MS tissue are described,
although their frequency remains to be established. OLs in
situ do not appear to express MHC molecules, prerequisites
for recognition by antigen-specific T cells (8). OLs in vitro
are susceptible to non-MHC–restricted injury mediated ei-
ther via soluble factor–dependent mechanisms (9–14) or
cell–cell contact–dependent mechanisms (11, 15–19). Pro-
longed exposure to TNF-
 
a
 
 or -
 
b
 
 induces apoptotic cell
death in OLs after 72–96 h (10–12). Mitogen-activated or
myelin-reactive CD4
 
1
 
 T cells acting in a non-MHC–
restricted manner can induce lysis of OLs without prior
apoptosis (19).
Fas is a cell surface receptor belonging to the TNF re-
ceptor superfamily that transduces cell death signals when
ligated by agonist antibodies or by fas ligand fasL (20, 21).
Although fas signaling usually induces apoptotic cell death,
fas ligation has been shown to trigger other cellular re-
sponses including proliferation (22). CD4
 
1
 
 and CD8
 
1
 
T cells (21) and macrophages (23), cell types found within ac-
tive MS lesions (4), all express fasL and in vitro can induce
injury via engagement of fas on target cells (23–28). Al-
though, in initial studies, fas was not detected in the unin-
jured brain (29, 30), recent reports suggest that fas expres-
sion can be induced in pathological conditions such as
 
1
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 BCIP, brom-chlor-indolyl phosphate;
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9
 
-diaminobenzidine; fasL, fas ligand; GalC, galactocerebro-
side; GFAP, glial fibrillary acidic protein; hsp, heat shock protein; LDH,
lactate dehydrogenase; MS, multiple sclerosis; NBT, nitroblue tetrazo-
lium; OL, oligodendrocyte; OND, other neurological diseases; PI, pro-
pidium iodide; TdT, terminal transferase; TUNEL, TdT-mediated
dUTP-biotin nick-end-labeling; UTP, uridine triphosphate.
  
2362
 
Fas Signaling in Oligodendrocyte Cell Death
 
cerebral ischemia (30) and Alzheimer’s disease (31). To es-
tablish the potential involvement of fas in OL cell death in
MS, we have assessed fas expression on OLs in MS tissue
in situ and the susceptibility of OLs to fas-mediated injury
in vitro.
 
Materials and Methods
 
Expression of Fas and Related Molecules in Normal and
MS CNS Tissue
 
Tissue Samples.
 
Early postmortem (between 4 and 8 h) CNS
tissue was obtained from 10 subjects with a clinical diagnosis of
chronic progressive MS (mean age of 46 yr). Two patients were
assigned a pathological classification of chronic active and two a
classification of chronic silent MS. A minimum of three blocks
were studied from each case for a total of 10 active and 27 silent
lesions. Normal CNS tissue came from three subjects (mean age
of 59 yr) succumbing to nonneurological conditions (lung cancer
and acute myocardial infarctions). In addition, brain tissue from
five other subjects with different neurologic diseases (OND) was
examined for control purposes. These included one case of tropi-
cal spastic paraparesis (inflammatory control) and one case each of
Alzheimer’s disease, ischemic stroke, amyotrophic lateral sclerosis,
and cerebral metastases from prostate cancer. The mean postmortem
delay for the OND cases was 8 h. All tissue was embedded in
O.C.T. (Miles, Elkhart, IN) medium and stored at 
 
2
 
70
 
8
 
C until use.
 
Immunohistochemistry.
 
Frozen sections were air-dried and then
fixed in 4% paraformaldehyde for 10 min. After quenching with
0.03% hydrogen peroxide and blocking with normal serum, sections
were incubated overnight with primary antibody. Monoclonal
IgG
 
1
 
 anti-fas antibody M3 was incubated at room temperature at a
dilution of 1:200, whereas monoclonal IgM antibody Leu-7 (Bec-
ton Dickinson, San Jose, CA) and two polyclonal antisera recog-
nizing different epitopes on human fasL protein (Santa Cruz Bio-
technology, Santa Cruz, CA) and CNPase were used overnight at
4
 
8
 
C at 1:800, 1:3200, and 1:100 dilution, respectively. Appropri-
ate secondary biotinylated antibodies were applied for 60 min at
room temperature followed by avidin-biotin-complex Elite re-
agent (Vector Labs, Inc., Burlingame, CA) for a further 45 min.
The chromogen was 3,3
 
9
 
-diaminobenzidine (DAB). For double-
staining, after incubation with M3 mAb for fas antigen and visual-
ization with DAB, sections were incubated with Leu-7 IgM mAb
followed by an anti–mouse 
 
m
 
 chain–specific secondary antibody
coupled to alkaline phosphatase and nitroblue tetrazolium (NBT)/
brom-chlor-indolyl phosphate (BCIP) as substrate. Negative con-
trols included omission of the primary antibody and the use of
isotype-specific, irrelevant antibodies. In addition, preabsorption
with the inhibitor peptides (1 
 
m
 
g per ml, Santa Cruz Biotechnol-
ogy) was performed on the two fasL antisera.
 
Establishment of Human CNS–derived Glial Cell Cultures.
 
Human
brain tissue was obtained from patients undergoing temporal lobe
resection or callosotomy as part of a surgical therapeutic treatment
for intractable epilepsy. The glial cell isolation procedure has pre-
viously been described (32). Briefly, the brain tissue was subjected
to enzymatic dissociation by using trypsin (0.25%; GIBCO BRL,
Burlington, Ontario, Canada) and DNase I (25 
 
m
 
g/ml; Boeh-
ringer Mannheim, Laval, Quebec) for 30 min at 37
 
8
 
C and me-
chanical dissociation by passage through a 132-
 
m
 
m nylon mesh
(Industrial Fabrics Corporation, Minneapolis, MN). Mixed glial
cells, consisting of 
 
z
 
70% OLs, 25% microglia, and 5% astrocytes
(assessed by 2
 
9
 
:3
 
9
 
-cyclic nucleotide phosphodiesterase [CNPase],
 
LeuM5, and glial fibrillary acidic protein [GFAP] immunoreac-
tivity, respectively) were obtained by separation on a 30% Percoll
(Pharmacia LKB, Montreal, Quebec) gradient (15,000 rpm at 4
 
8
 
C
for 30 min). To enrich for OLs, freshly isolated mixed glial cells
were left overnight in Falcon tissue culture flasks (VWR, Mon-
treal, Québec), and the less adherent OLs were removed by gen-
tle shaking. The differential adhesion protocol was repeated 24 h
later on this semi-enriched OL culture. This population of OLs
was identified using rabbit anti–3
 
9
 
:5
 
9
 
-CNPase polyclonal anti-
body, a marker for mature OLs (1 h at 1:40 dilution; gift from
Dr. Peter Braun, McGill University, Montreal, Canada), followed
by goat anti–rabbit IgG conjugated with Texas red (1 h at 1:100
dilution; Jackson ImmunoResearch Labs, Inc., West Grove, PA)
and was found to contain 
 
.
 
90% OLs. The derived OLs were plated
onto poly-
 
l
 
-lysine–coated (10 
 
m
 
g/ml; Sigma, St. Louis, MO)
Aclar 9-mm diameter coverslips or into 96-well Nuntron plates
(Becton Dickinson, Mountain View, CA) at a density of 5 
 
3
 
 10
 
4
 
cells per coverslip or microwell; coverslips were placed in Nun-
tron petri dishes. Microwells or petri dishes were filled with min-
imum essential culture medium supplemented with 5% FCS, 2.5
U/ml penicillin, 2.5 
 
m
 
g/ml streptomycin, and 0.1% glucose (all
from GIBCO BRL). The OLs were allowed to extend processes
and were used in functional assays 2–4 wk from the time of isola-
tion. At this time, the OL preparations lacked endothelial and fi-
broblast cell contamination (32). The remaining adherent popula-
tions containing astrocytes and microglia were trypsinized and
plated as described for the OLs to give mixed astrocyte-microglia
cultures (
 
<
 
30% astrocytes); pure microglia cultures (
 
.
 
95% en-
riched) were obtained by shaking the less adherent astrocytes off
(5 h on a rotary shaker in a humidified incubator maintained at 37
 
8
 
C
and 5% CO
 
2
 
) and trypinizing and plating the cells as described for
the OLs. Astrocytes were identified using polyclonal rabbit anti-
GFAP (1 h at 1:100 dilution; Boehringer Mannheim), followed
by goat anti–rabbit Ig conjugated with Texas red (1 h at 1:100 di-
lution), and microglia were identified using an anti-LeuM5 (1 h,
neat; Becton Dickinson), followed by Texas red–conjugated goat
anti–mouse IgG2b Ab (Jackson ImmunoResearch Labs Inc.).
 
Expression of Fas on Human Adult Glial Cells In Vitro.
 
To de-
termine whether target cells expressed fas, live unfixed target cells
on coverslips were incubated with either M3 or M33, activating
and nonactivating anti-fas IgG
 
1
 
 monoclonal antibodies, respec-
tively (1 h at 5 
 
m
 
g/ml; Immunex Corp., Seattle, WA), followed
by biotinylated goat anti–mouse IgG (1 h at 1:100 dilution; Boeh-
ringer Mannheim), followed by FITC-conjugated Streptavidin (1 h
at 1:20 dilution) (Boehringer Mannheim). The cells were then
fixed in acid/alcohol (5% glacial acetic acid/95% absolute ethanol).
OLs were identified by anti-CNPase immunostaining; astrocytes
were identified by anti-GFAP immunostaining, and microglia, af-
ter blocking with mouse serum for 30 min, were identified by
anti-LeuM5 immunostaining, as described above. Glial cell fas
immunoreactivity (IR) was compared with fas IR on a panel of
fas-expressing (U251 glioma cells, Jurkat T cells, U937 mono-
cytic cells) and fas-nonexpressing (L929 fibroblast cells) cell lines;
the cell lines used in this study were single-stained for fas IR, as
described above. Immunocytochemical analysis was performed
using either a Reichert Polyvar 2 Leica immunofluorescence mi-
croscope or, for the OLs, a confocal laser scanning microscope
(Leica Lasertechnik, Heidelberg, Germany). Negative controls
included omission of the primary antibody and the use of isotype-
specific, irrelevant antibody. Samples were scanned with a 40 
 
3
 
1.3 NA oil immersion objective with a band pass filter peaking at
535 
 
6
 
 7 nm for FITC specificity and a 580-nm-high pass filter
for Texas red. 
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Cell Death Assays
 
Membrane Injury: Lactate Dehydrogenase Release Assay and Trypan
Blue Uptake.
 
As previously described (11), cell-free supernate
was collected from OL cultures exposed to fas ligation. Sample
tubes containing 0.5 ml of 2 mg/ml NADH, 0.5 ml of 1.5 mmol/l
pyruvate substrate, and 100 
 
m
 
l of test sample were incubated for
30 min at 37
 
8
 
C. Pyruvate calibration curve tubes were set up. 1 ml
of color reagent was added to each tube to stop the reaction. Ab-
sorbency was read at 460 nm. Test sample lactate dehydrogenase
(LDH) was calculated by comparison with a curve generated us-
ing the pyruvate standards.
To assess trypan blue uptake, trypan blue (Sigma) was added at
a 1:1 dilution to cell cultures previously exposed to fas ligation. Cells
staining blue, indicating membrane disruption, were counted and
expressed as a percentage of the total number of cells counted.
 
Nuclear Injury: Propidium Iodide and TUNEL Labeling
 
Nuclear
fragmentation was assessed morphologically (nuclear fragmenta-
tion and chromatin condensation) by propidium iodide (PI) stain-
ing (10 
 
m
 
g/ml for 20 min on coverslips fixed with acetone/meth-
anol 1:1 for 10 min at 
 
2
 
20
 
8
 
C), as previously described (11). DNA
fragmentation was assessed using the terminal transferase (TdT)–
mediated (d-uridine triphosphate [UTP])-biotin nick-end-labeling
(TUNEL) technique, as previously described (11). For adherent
target cells (OL, astrocytes, microglia, U251 glioma cells, and
L929 cells), coverslips were fixed in acetone/methanol (1:1) for
10 min at 
 
2
 
20
 
8
 
C; nonadherent target cells were cytospun onto
gelatin-coated slides and then fixed in acetone/methanol as de-
scribed above. After rehydration for 30 min in PBS, cells were in-
cubated for 1 h at 37
 
8
 
C with 50 
 
m
 
l of nick-end-labeling solution
containing TdT (0.3 U/ml) and biotinylated dUTP (0.01 nmol/
ml) in TdT buffer (Promega, Madison, WI). The reaction was
terminated by incubation in Tris buffer (10 mM Tris-HCl, pH
6.8, for 15 min). After blocking with 2% BSA for 15 min, the
cells were incubated with streptavidin-FITC (1:20 dilution, 30
min at 37
 
8
 
C; Boehringer Mannheim). Hoechst dye 33258 (10
 
m
 
g/ml, 20 min; Sigma) was used to identify target cell nuclei.
For each experiment (
 
n
 
), 200–400 cells were counted per cov-
erslip, and counting was done by an observer blinded to the treat-
ment received by the cells. Each test condition was assessed in
triplicate per experiment.
 
Results
 
Expression of Fas and Related Molecules in Normal and MS
CNS Tissue In Situ.
 
In normal CNS white matter, faint
fas immunoreactivity was detected on scattered glial cells by
immunohistochemistry using the M3 mAb. This occurred
on cells with small, round nuclei, a thin rim of cytoplasm,
and one or two tenous processes (Fig. 1 
 
a
 
). Such elements
were identified as OLs by their morphologic phenotype
and positive staining for Leu-7 and CNPase in serial sec-
tions. Fas was also constitutively expressed on endothelial
cells of small blood vessels. Other glial cells and neurons
were invariably fas-negative. Immunostaining for fasL on
normal CNS tissue revealed low-level constitutive reactiv-
ity on microglial cells (Fig. 1 
 
b
 
). The specificity of the fasL
reactivity was confirmed by peptide preabsorption, the lat-
% apoptotic nuclei number of TUNEL
   + nuclei
number of Hoechst labeled nuclei
---------------------------------------------------------------------------------- 100% ´ =
 
ter resulting in a lack of fasL immunoreactivity. In tissue
from all cases of MS, fas reactivity was prominent on OLs
along the margin of lesions and in adjacent white matter
(Fig. 1, 
 
c
 
 and 
 
d
 
). These same cells also stained positively for
CNPase and Leu-7 in serial sections (Fig. 1 
 
e
 
), although the
pattern of staining was different with Leu-7 and CNPase
staining the cell body and M3, the cell membrane, and its
fine processes. Definitive identification of these cells as fas-
positive oligodendrocytes was confirmed by double-stain-
ing with M3 and Leu-7 antibodies (Fig. 1 
 
f
 
). Fas IR on
OLs in MS lesions was confirmed using another anti-fas
mAb, UB2 (Immunotech Inc., Westbrook, ME), and similar
results were obtained (data not shown). Apart from endo-
thelial cells and infiltrating lymphocytes (Fig. 1 
 
g
 
), no other
cell type showed fas reactivity. Staining for fas ligand in MS
lesions (Fig. 1 
 
h
 
) revealed intense positivity on microglia
and scattered infiltrating lymphocytes but not on OLs or
astrocytes. In sections from OND cases, immunostaining
for fas and fasL was comparable to the normal controls.
 
Expression of Fas on Human Adult Glial Cells In Vitro.
 
To determine whether human adult CNS–derived glial
cells were capable of expressing cell surface fas, fas IR on
2–4-wk-old glial cell cultures was examined using an anti-
fas IgG
 
1
 
 (M3) mAb and compared with that on known fas-
expressing cells, including the Jurkat T cell line (33, 34),
U937 myeloid leukemia cells (35), U251 human glioma
(malignant astrocyte) cells (36), and on the known fas-neg-
ative L929 mouse fibroblast cell line (33). The majority of
OLs (79 
 
6
 
 4%, 
 
n
 
 
 
5
 
 4 as determined by CNPase/fas dou-
ble-immunolabeling) expressed fas with fas IR extending
well out onto processes (Fig. 2), whereas microglia and as-
trocytes were fas-negative (Fig. 3). Fas IR using the M3
mAb on OLs was confirmed using another anti-fas mAb,
M33 (Immunex Corp.), and similar staining patterns were
observed (data not shown).
 
Susceptibility of Human Adult Glial Cells to Fas-mediated In-
jury.
 
We next investigated whether human OLs were
susceptible to fas-mediated injury. Anti-fas M3 mAb (37;
25 
 
m
 
g/ml; 24 h incubation) was added to cultures of either
adult human CNS–derived OLs, microglia, mixed astro-
cyte-microglia, or the cell targets cited above. Cross-link-
ing with anti-IgG
 
1
 
 mAb for 24 h induced membrane injury
of OLs to an extent comparable to other fas-susceptible
cells, including the malignant astrocyte cell line (U251), as
measured by LDH release; microglia and the L929 cell line
were resistant to membrane injury (Fig. 4). OL membrane
injury by fas ligation with M3 was confirmed by trypan
blue uptake (62.5 
 
6
 
 9.2% trypan blue positive cells, com-
pared with control cultures of 1.4 
 
6
 
 0.8%, 
 
n
 
 
 
5
 
 4). Lack of
pure cultures prevented testing of astrocytes in the LDH as-
say; however, the trypan blue uptake assay revealed no loss
of membrane integrity and cell viability in mixed astrocyte-
microglia cultures upon fas ligation (4.4 
 
6
 
 2.1% trypan
positive cells compared with control cultures of 3.6 
 
6
 
1.3%, 
 
n
 
 
 
5
 
 3). In contrast to other fas-susceptible cells, no
nuclear or DNA fragmentation concomitant with mem-
brane injury was observed in OLs after 24 h of fas ligation 
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with M3 mAb, as assessed morphologically by PI staining
(Fig. 4) or by the TUNEL technique (5.8 
 
6
 
 1.0% com-
pared with control conditions of 3.6 
 
6
 
 2.3%, 
 
n
 
 
 
5
 
 3).
Within the first 24 h after fas ligation, there was no signifi-
cant change in the number of adherent OLs (92.5 
 
6
 
 3.5%
of the untreated control cultures, 
 
n 5 4), despite the LDH
release; significant OL process retraction, however, was evi-
dent. After 4 d, significant cell loss was apparent (25.3 6
7.2% of the untreated control cultures, n 5 4). In all target
cells tested, replacement of anti-fas M3 mAb with a nonac-
tivating anti-fas (M33) mAb (37), with antigalactocerebro-
side, an OL-specific cell surface–expressed molecule, or
with anti-IgG1 mAb alone did not induce significant injury
compared with control cultures (see Fig. 4 legend).
As shown in Table 1, after a 24 h exposure to a 1:10 di-
lution of human fasL prepared in yeast medium (Immunex
Corp.), 56% of OLs failed to exclude trypan blue; only rare
cells showed evidence of nuclear condensation or fragmen-
tation. In contrast, glioma cells showed evidence of both
membrane and nuclear injury.
Induction of Rapid and Delayed Apoptotic Responses in Hu-
man Adult Oligodendrocytes. The lack of apoptosis before
or concomitant with membrane injury in OLs upon fas li-
gation contrasts with previous findings using other cell tar-
gets in which fas ligation is associated with induction of
apoptotic cell death. Our findings could reflect that OLs
have an indolent apoptotic program that is not activated after
24 h of fas ligation. In this regard, we have previously dem-
Figure 1. Expression of fas and related molecules in normal and MS CNS tissue. (a) Normal human white matter reacted with M3 anti-fas mAb. Note
the faintly positive cells (brown) that have the morphology of oligodendrocytes. Frozen section: DAB-reacted and counterstained with hematoxylin. (b)
Normal human white matter immunoreactive for fasL. Note the faint positivity on the fine processes of the ramified microglial cells. Frozen section:
DAB and hematoxylin. (c) White matter adjacent to a chronic active MS lesion shows numerous fas-positive interfascicular oligodendrocytes (brown).
DAB and hematoxylin. (d) Detail of fas-positive oligodendrocytes from the edge of a chronic silent MS lesion. Note the typical bipolar outline of the
cells. DAB and hematoxylin. (e) Interfascicular oligodendrocytes in white matter adjacent to a chronic silent MS lesion show positive immunoreactivity
for Leu-7. Similar, but less intense staining was obtained with anti-CNPase antiserum. DAB and hematoxylin. (f) Double-staining of interfascicular oli-
godendrocytes from white matter adjacent to a chronic silent lesion with M3 and Leu-7 (Brown and blue, respectively). DAB and NBT/BCIP. No coun-
terstain. (g) The edge of a chronic active MS lesion shows fas-positive infiltrating cells around a blood vessel. DAB-immunoreacted, no counterstain. (h)
Microglial cells at the periphery of a chronic silent MS lesion display intense immunoreactivity for fasL. DAB and hematoxylin. Original magnifications:
(A, D, F, G) 3750; (B, C, E, H) 3300.
Figure 2. Fas expression on human
adult CNS-derived oligodendrocytes
as assessed by confocal laser scanning
microscopy. Human oligodendrocytes
were maintained in 5% serum-supple-
mented culture medium for 3 wk and
assessed for (A) fas immunoreactivity
(green) and (B) CNPase immunoreac-
tivity (red). (C) Double-staining is de-
picted by superimposing the fas (green)
and CNPase (red) images, in which
yellow indicates colocalization of the
fas and CNPase signal. (D) An irrele-
vant IgG1 mAb isotype control for
oligodendrocyte immunostaining.2366 Fas Signaling in Oligodendrocyte Cell Death
onstrated that TNF-a or serum deprivation induces a de-
layed apoptotic response in human OLs after 72–96 h of
exposure (11). However, the addition of membrane-solu-
ble C2-ceramide (50 mM), an analogue of the complex
lipid ceramide, a molecule that has been implicated in apop-
totic signaling pathways (38–42), induced rapid apoptosis
of OLs within 18 h, as determined by the TUNEL technique
(52.6 6 4.4% apoptotic cells compared with control condi-
tions of 4.6 6 1.3%, n 5 5; Fig. 5). In addition, fas ligation
of OLs for 96 h did not induce apoptosis (both adherent
Figure 3. Fas expression on human adult
CNS-derived astrocytes, microglial cells, and
known fas-expressing (U251 glioma cells, Jur-
kat T cells, and U937 myeloid leukemia cells)
and fas-negative cells (L929 fibroblast cells).
Panels A and B represent adult astrocytes: (A)
lack of fas immunoreactivity on astrocytes and
(B) GFAP immunoreactivity of the same field
as in A to identify astrocytes. Panels C and D
represent adult microglial cells. (C) lack of fas
immunoreactivity on microglia and (D) Leu
M5 immunoreactivity of the same field as in C
to identify microglia. The remainder of the
panels represent fas immunoreactivity on (E)
U251 glioma cells, (F) Jurkat T cells, (G)
U937 myeloid leukemia cells, and (H) L929
fibroblast cells. Original magnifications: (A, B,
E, H) 3400; (C, D, F) 3250.
Figure 4. Mean LDH release in units per milliliter (unshaded bars) and
mean percentage of fragmented nuclei as assessed by PI staining (shaded
bars) for the indicated cell targets treated with anti-fas IgG1 (M3) (25 mg/ml;
24 h) mAb followed by cross-linking with anti-IgG1 mAb (1:100 dilu-
tion; 24 h). Mean LDH release for control target cells or target cells
treated with anti-fas (M3) mAb alone or nonactivating fas (M33) mAb
followed by cross-linking with anti-IgG1 or anti-IgG1 alone was ,200
U/ml. n represents the number of LDH experiments performed; for PI
staining studies, n 5 3. For LDH and PI studies, each test condition was
assessed in triplicate per experiment. 2367 D’Souza et al.
and nonadherent OL cell populations were assessed), as
assessed by the TUNEL technique (6.3 6 2.1%, n 5 3).
Taken together, these data suggest that whereas OLs have
the capability of undergoing both rapid and delayed apop-
totic responses upon exposure to C2-ceramide and TNF-a,
respectively, their response to fas ligation does not involve
apoptosis but rather lysis.
Discussion
In this report, we describe results from in situ and in
vitro studies that support a role for fas-mediated signaling
in the susceptibility of OLs to immune-mediated injury,
information of relevance to the pathogenesis of MS. The in
situ studies demonstrate the upregulation of fas expression
on OLs in the regions of active MS lesions to levels dis-
tinctly higher than seen in normal and OND controls. The
in vitro studies indicated that among human CNS glial
cells, OLs selectively express fas, resulting in their differen-
tial susceptibility to injury via this pathway. Although hu-
man OLs are capable of undergoing apoptotic responses,
either rapidly as shown in this study using C2-ceramide or
in a delayed manner in response to TNF or serum depriva-
tion (11), their response to fas ligation, as assessed using ei-
ther a fas receptor activating antibody or fas ligand, involves
a lytic rather than an apoptotic form of cell injury. Cross-
ligation of antibodies directed against other surface molecules
expressed on OLs, including anti-GalC and nonactivating
anti-fas mAb M33 did not induce lysis of OLs, excluding
the possibility that the novel lytic response of OLs to fas li-
gation was due to complement-mediated lysis. A lytic re-
sponse of OLs in vivo could result in the release of myelin
antigens, thus provoking further inflammation. Most previ-
ous cytotoxicity studies involving fas-mediated target cell
injury have involved the use of proliferating targets; mature
OLs rarely, if ever, divide in culture (43). It is possible that
end-mitotic cells such as OLs may employ a fas signal trans-
duction pathway that is different from proliferating targets,
or alternatively, the cell cycle may play a role in shaping the
cell death response triggered by fas ligation. This would be
in keeping with our previous data in which CD41 ab T
cells, widely known to employ the fas pathway in effecting
target cell injury (25, 26), induced apoptotic lysis in prolif-
erating U251 glioma cells but induced lysis without prior
DNA fragmentation in OLs. The existence of different cell in-
jury mechanisms (lysis and apoptosis) of OLs have therapeutic
implications. We have previously demonstrated (44), as re-
ported by others (45, 46), that CNTF selectively protects
OLs from nuclear-directed but not lytic cell death.
Our finding that OL cell loss does not occur after 24 h of
fas ligation, despite LDH release, raises the possibility that
fas ligation could result in sublethal injury of OLs, affecting
their capacity to maintain their myelin without actual cell
body loss. The significant retraction of OL processes ob-
served during the period of fas ligation supports this con-
tention. We have previously shown that CD41 T cells acti-
vated with anti-CD3 mAb and interleukin-2 also induces
LDH or 51chromium release from human OLs without OL
Table 1. Fas Ligand–Induced Injury of Human OLs
Target cell
OLs U251 glioma
Effector
Trypan blue
uptake
PI nuclear
stain
Trypan blue
uptake
PI nuclear
stain
FasL 56 6 2% 3 6 1% 78 6 9% 69 6 8%
Yeast
supernatant 4 6 1% 1 6 0.4% 5 6 1% 1 6 1%
Culture
medium 1 6 0.2% 2 6 1% 2 6 0.4% 2 6 1%
Data indicate the percentage 6 SEM of triplicate experiments of un-
fixed OLs or glioma cells, which take up trypan blue or shown nuclear
condensation or fragmentation after fixation and staining with PI in re-
sponse to a 24-h exposure to fasL (1:10 dilution). Controls were either
yeast medium used to prepare the fasL or culture medium alone.
Figure 5. Induction of DNA fragmentation in human adult CNS-derived oligodendrocytes, as assessed by the TUNEL technique (A) after exposure to
C-2 ceramide (50 mM) for 18 h. B represents oligodendrocytes under control culture conditions. Original magnification 3250.2368 Fas Signaling in Oligodendrocyte Cell Death
cell loss (11). The timing of OL depletion in MS remains
to be defined, although the consensus of most studies is that
depletion is a late event (5). The delayed OL cell loss that
occurred in vitro upon more prolonged fas ligation could
thus reflect the findings in more established MS lesions.
Our demonstration of upregulation of fas-ligand expres-
sion on endogenous microglia (scattered infiltrating lym-
phocytes also expressed fas ligand), in active MS lesions
compared with control CNS tissue, further implicates fas
signaling as a potential mechanism for MHC unrestricted
OL injury in MS. Such upregulation could reflect the ef-
fects of inflammatory mediators in the MS plaque milieu
(5), in a manner akin to cytokine (IFN-g)-induced upregu-
lation of fas on lymphocytes (47, 48). In fact, IFN-g and
LPS, known activators of microglia (49), in combination,
upregulate fas-ligand expression on human microglia in vitro
(B. Bonetti, S.D. D’Souza, J.P. Antel, and C.S. Raine,
manuscript in preparation). Mechanisms for selective OL
injury in MS are of particular interest in that OLs in situ do
not express MHC molecules, prerequisites for antigen-spe-
cific interaction with cytotoxic T cells (8). Whereas MHC
unrestricted mechanisms of OL injury have been postu-
lated, the apparent lack of specificity of these mechanisms
raises the issue as to how such mechanisms could selectively
injure OLs and spare other neural cells in MS. One possible
explanation could be that OLs are selectively vulnerable to
these immune effector mechanisms. We have previously
shown that human OLs, among other human CNS-derived
cells, are selectively vulnerable to TNF-mediated apoptosis
(11). Canine OLs have been shown to be selectively vul-
nerable to reactive oxygen species (50). Another possible
explanation could be that certain immune recognition
molecules are selectively upregulated on OLs in MS le-
sions. In this regard, previous studies have shown that OLs
in MS lesions selectively express heat shock proteins (hsp),
such as hsp-60 (51), and hsps have been postulated as puta-
tive ligands for cytolytic gd–T cells (52, 53). In vitro stud-
ies on human OLs have shown that the cytokine interleu-
kin-1 selectively upregulates hsp-72 expression on OLs (54)
and that gd–T cells are lytic to human OLs in vitro (16).
Our demonstration here that fas is selectively upregulated
on OLs in MS lesions provides a further basis for the selec-
tive OL injury in MS. The availability of soluble fas, neu-
tralizing antibodies to fas or fas ligand, or inhibitors of fas
ligand induction or fas-mediated cell death provides poten-
tial means to manipulate this signaling pathway for thera-
peutic applications in MS.
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